IMM01
Phase 3Biologic
IMM01 is one of 97 biologic programs targeting Lymphoma. It is currently in Phase 3.
3
Indications
6
Total Trials
3
Active Trials
96
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
401 competitors in Lymphoma
#DrugCompanyPhaseTrials
1IMM01
IImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 3
Zofran
NovartisPreclinical
Cabenuva
GSKPreclinical
Norvir
AbbViePreclinical
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
Nuvigil
NNuvo Research GmbH
Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lymphoma2 trials
Recurrent Hematologic Malignancy1 trial
Myelodysplastic Syndrome1 trial
Patients With Advanced Solid Tumors1 trial
A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors
Not yet recruiting·IImmuneOnco Biopharmaceuticals (Shanghai) Inc.·Phase 1/2·NCT07170787·104 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IMM01. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details